Talebi Zahra, Sparreboom Alex, Colace Susan I
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Division of Pharmaceutics and Pharmacology, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Methods Mol Biol. 2022;2547:47-61. doi: 10.1007/978-1-0716-2573-6_3.
Targeted therapies have significantly altered the landscape of available cancer therapies across all diagnoses and patient populations, and supportive care therapies have steadily improved throughout the years to make therapy more tolerable for patients. Even so, these therapies have varied efficacy and toxicity among patients with cancer, and pharmacogenomics presents an opportunity to identify which patients are most at risk of toxicities and most likely to benefit from them. While the field of pharmacogenomics in targeted cancer therapy is still growing, we review current knowledge, hypotheses, and clinical practices in this chapter, along with a brief review of pharmacogenomics in supportive therapies in cancer treatment.
靶向治疗显著改变了所有诊断类型和患者群体中可用癌症治疗的格局，并且多年来支持性护理治疗也在稳步改善，以使治疗对患者来说更易于耐受。即便如此，这些治疗在癌症患者中的疗效和毒性各不相同，而药物基因组学提供了一个机会，来确定哪些患者发生毒性的风险最高以及最有可能从这些治疗中获益。虽然靶向癌症治疗中的药物基因组学领域仍在发展，但我们在本章中回顾了当前的知识、假说和临床实践，同时简要回顾了癌症治疗中支持性疗法的药物基因组学。
